Unaudited Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Total | Common stock | Additional paid-in capital | Accumulated other comprehensive (loss) income | Accumulated deficit | Noncontrolling interests |
Beginning balance (in shares) at Dec. 31, 2022 | 8,700,885 | | | | | |
Beginning balance at Dec. 31, 2022 | $ 107,808 | | | | | |
Convertible preferred stock | | | | | | |
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares) | (8,700,885) | | | | | |
Conversion of convertible preferred stock and non-controlling interests to common stock | $ (107,808) | | | | | |
Ending balance (in shares) at Mar. 31, 2023 | 0 | | | | | |
Ending balance at Mar. 31, 2023 | $ 0 | | | | | |
Beginning balance (in shares) at Dec. 31, 2022 | | 2,217,737 | | | | |
Beginning balance at Dec. 31, 2022 | (142,670) | $ 2 | $ 1,197 | $ (41) | $ (158,223) | $ 14,395 |
Stockholders’ Equity (Deficit) | | | | | | |
Stock-based compensation | 265 | $ 0 | 265 | | | |
Unrealized gain on marketable securities | 177 | | | 177 | | |
Issuance of common stock for cash in pre-closing financing (in shares) | | 3,730,608 | | | | |
Issuance of common stock for cash in pre-closing financing | 30,640 | $ 4 | 30,636 | | | |
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares) | | 5,059,338 | | | | |
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability | 42,447 | $ 5 | 42,442 | | | |
Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares) | | 10,374,272 | | | | |
Issuance of common stock to Sesen Bio shareholders in reverse capitalization | 72,044 | $ 10 | 72,034 | | | |
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares) | | 18,872,711 | | | | |
Conversion of convertible preferred stock and non-controlling interests to common stock | 107,809 | $ 19 | 122,185 | | | (14,395) |
Net loss | (24,642) | | | | (24,642) | |
Ending balance (in shares) at Mar. 31, 2023 | | 40,254,666 | | | | |
Ending balance at Mar. 31, 2023 | $ 86,070 | $ 40 | 268,759 | 136 | (182,865) | 0 |
Beginning balance (in shares) at Dec. 31, 2022 | 8,700,885 | | | | | |
Beginning balance at Dec. 31, 2022 | $ 107,808 | | | | | |
Ending balance (in shares) at Sep. 30, 2023 | 0 | | | | | |
Ending balance at Sep. 30, 2023 | $ 0 | | | | | |
Beginning balance (in shares) at Dec. 31, 2022 | | 2,217,737 | | | | |
Beginning balance at Dec. 31, 2022 | (142,670) | $ 2 | 1,197 | (41) | (158,223) | 14,395 |
Stockholders’ Equity (Deficit) | | | | | | |
Unrealized gain on marketable securities | 414 | | | | | |
Net loss | (65,921) | | | | | |
Ending balance (in shares) at Sep. 30, 2023 | | 40,304,436 | | | | |
Ending balance at Sep. 30, 2023 | $ 46,298 | $ 40 | 270,029 | 373 | (224,144) | 0 |
Beginning balance (in shares) at Mar. 31, 2023 | 0 | | | | | |
Beginning balance at Mar. 31, 2023 | $ 0 | | | | | |
Ending balance (in shares) at Jun. 30, 2023 | 0 | | | | | |
Ending balance at Jun. 30, 2023 | $ 0 | | | | | |
Beginning balance (in shares) at Mar. 31, 2023 | | 40,254,666 | | | | |
Beginning balance at Mar. 31, 2023 | 86,070 | $ 40 | 268,759 | 136 | (182,865) | 0 |
Stockholders’ Equity (Deficit) | | | | | | |
Exercise of stock options (in shares) | | 14,910 | | | | |
Exercise of stock options | 52 | | 52 | | | |
Stock-based compensation | 330 | $ 0 | 330 | | | |
Unrealized gain on marketable securities | 129 | | | 129 | | |
Net loss | (19,876) | | | | (19,876) | |
Ending balance (in shares) at Jun. 30, 2023 | | 40,269,576 | | | | |
Ending balance at Jun. 30, 2023 | $ 66,705 | $ 40 | 269,141 | 265 | (202,741) | 0 |
Ending balance (in shares) at Sep. 30, 2023 | 0 | | | | | |
Ending balance at Sep. 30, 2023 | $ 0 | | | | | |
Stockholders’ Equity (Deficit) | | | | | | |
Exercise of stock options (in shares) | | 34,860 | | | | |
Exercise of stock options | 40 | | 40 | | | |
Stock-based compensation | 848 | | 848 | | | |
Unrealized gain on marketable securities | 108 | | | 108 | | |
Net loss | (21,403) | | | | (21,403) | |
Ending balance (in shares) at Sep. 30, 2023 | | 40,304,436 | | | | |
Ending balance at Sep. 30, 2023 | $ 46,298 | $ 40 | 270,029 | 373 | (224,144) | 0 |
Beginning balance (in shares) at Dec. 31, 2023 | 0 | | | | | |
Beginning balance at Dec. 31, 2023 | $ 0 | | | | | |
Ending balance (in shares) at Mar. 31, 2024 | 0 | | | | | |
Ending balance at Mar. 31, 2024 | $ 0 | | | | | |
Beginning balance (in shares) at Dec. 31, 2023 | | 40,609,915 | | | | |
Beginning balance at Dec. 31, 2023 | 26,532 | $ 40 | 271,594 | 0 | (245,102) | 0 |
Stockholders’ Equity (Deficit) | | | | | | |
Exercise of stock options (in shares) | | 1,579 | | | | |
Exercise of stock options | 2 | | 2 | | | |
Stock-based compensation | 1,057 | $ 0 | 1,057 | | | |
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares) | | 931,250 | | | | |
Sale of common stock under Open Market Sales Agreement, net of issuance costs | 2,282 | $ 1 | 2,281 | | | |
Net loss | (18,978) | | | | (18,978) | |
Ending balance (in shares) at Mar. 31, 2024 | | 41,542,744 | | | | |
Ending balance at Mar. 31, 2024 | $ 10,895 | $ 41 | 274,934 | 0 | (264,080) | 0 |
Beginning balance (in shares) at Dec. 31, 2023 | 0 | | | | | |
Beginning balance at Dec. 31, 2023 | $ 0 | | | | | |
Ending balance (in shares) at Sep. 30, 2024 | 0 | | | | | |
Ending balance at Sep. 30, 2024 | $ 0 | | | | | |
Beginning balance (in shares) at Dec. 31, 2023 | | 40,609,915 | | | | |
Beginning balance at Dec. 31, 2023 | $ 26,532 | $ 40 | 271,594 | 0 | (245,102) | 0 |
Stockholders’ Equity (Deficit) | | | | | | |
Exercise of stock options (in shares) | 3,810 | | | | | |
Unrealized gain on marketable securities | $ 0 | | | | | |
Net loss | (42,842) | | | | | |
Ending balance (in shares) at Sep. 30, 2024 | | 41,750,109 | | | | |
Ending balance at Sep. 30, 2024 | $ (11,126) | $ 41 | 276,777 | 0 | (287,944) | 0 |
Beginning balance (in shares) at Mar. 31, 2024 | 0 | | | | | |
Beginning balance at Mar. 31, 2024 | $ 0 | | | | | |
Ending balance (in shares) at Jun. 30, 2024 | 0 | | | | | |
Ending balance at Jun. 30, 2024 | $ 0 | | | | | |
Beginning balance (in shares) at Mar. 31, 2024 | | 41,542,744 | | | | |
Beginning balance at Mar. 31, 2024 | 10,895 | $ 41 | 274,934 | 0 | (264,080) | 0 |
Stockholders’ Equity (Deficit) | | | | | | |
Exercise of stock options (in shares) | | 2,231 | | | | |
Exercise of stock options | 2 | | 2 | | | |
Stock-based compensation | 625 | $ 0 | 625 | | | |
Net loss | (11,162) | | | | (11,162) | |
Ending balance (in shares) at Jun. 30, 2024 | | 41,544,975 | | | | |
Ending balance at Jun. 30, 2024 | $ 360 | $ 41 | 275,561 | 0 | (275,242) | 0 |
Ending balance (in shares) at Sep. 30, 2024 | 0 | | | | | |
Ending balance at Sep. 30, 2024 | $ 0 | | | | | |
Stockholders’ Equity (Deficit) | | | | | | |
Stock-based compensation | 1,115 | | 1,115 | | | |
Unrealized gain on marketable securities | 0 | | | | | |
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares) | | 205,134 | | | | |
Sale of common stock under Open Market Sales Agreement, net of issuance costs | 101 | | 101 | | | |
Net loss | (12,702) | | | | (12,702) | |
Ending balance (in shares) at Sep. 30, 2024 | | 41,750,109 | | | | |
Ending balance at Sep. 30, 2024 | $ (11,126) | $ 41 | $ 276,777 | $ 0 | $ (287,944) | $ 0 |